Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110669
Status:
COMPLETED
Last Update Posted:
2011-10-27
First Post:
2005-05-12
Brief Title:
High-dose Prednisone in Duchenne Muscular Dystrophy
Sponsor:
Cooperative International Neuromuscular Research Group
Organization:
Cooperative International Neuromuscular Research Group
Study Overview
Official Title:
A Randomized Study of Daily vs High-dose Weekly Prednisone Therapy in Duchenne Muscular Dystrophy
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will help to determine whether a high-dose weekly course of prednisone therapy is safer than and at least as effective as daily dose therapy for people with Duchenne muscular dystrophy DMD Boys who are enrolled in this study should not have taken carnitine other amino acids creatine glutamine Coenzyme Q10 or any herbal medicines within the last three months There will be a two-visit screening to take place in one week to ensure a reproducible manual muscle test The subject will then be randomized and put into either the daily or weekly regimen The duration of the study is twelve 28-day treatment cycles approximately 12 months with follow-up visits at month one three and then every three months
Detailed Description:
Duchenne muscular dystrophy DMD is the most common lethal inherited disorder worldwide Despite the exponential increase in our understanding of the disorder since the discovery and characterization of the causative gene and its product dystrophin in 1987 current therapeutic management remains largely supportive Awaiting a final genetic cure to be available in the future further investments in developing better drug therapies for DMD remain important The effect of a high dose prednisone regimen will be evaluated in comparison to a daily dose regimen in a multi-center randomized double-blind placebo-controlled 4-arm study Ambulant children aged 4-10 years with an established DMD diagnosis will be studied Patients will undergo 2 screening evaluations within 1 week Patients will be randomized into treatment groups on the second screening visit followed by a 12-month treatment period During the treatment period patients will be evaluated at monthly intervals The primary endpoints are percentage change in average muscle strength score and QMT performance for specific muscle groups Secondary endpoints include timed function tests functional grades for arms and legs and pulmonary function tests
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None